Adherence to HIV regimens: 10 vital lessons

American Journal of Nursing

Volumn 101, Issue 6, 2001, Pages 37-43

  Williams, Ann B ^a  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ADMINISTRATION; DRUG MONITORING; HEALTH BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; NURSING; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL MODEL; REVIEW; SOCIAL SUPPORT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; MODELS, PSYCHOLOGICAL; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; SOCIAL SUPPORT;

EID: 0039435012     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200106000-00019     Document Type: Article

References (15)

1. Cramer JA, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261(22):3273-7.
2. Wright EC. Non-compliance - or how many aunts has Matilda? Lancet 1993;342(8876):909-13.
3. Palella FJ, Jr., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60.
4. Haynes RB, et al. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979.
5. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993;153(16):1863-8.
6. Bangsberg DR, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14(4):357-66.
7. Paterson DL, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30.
8. Grodesk M, et al. Factors associated with Pneumocystis carinii pneumonia (PCP) in the setting of frequent use of PCP prophylaxis and highly active antiretroviral therapy (HAART). Presented at the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago. Abstract 739; 1998. http://www.retroconference.org/abstracts/abstracts/session92/739.htm.
9. Huang L, et al. Pneumocystis carinii pneumonia in the protease inhibitor era. Presented at the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago. Abstract 185; 1998. http://www.retroconference.org/abstracts/abstracts/session26/185.htm.
10. Holzemer WL, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999;13(3):185-97.
11. Roca B, et al. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. J Infect 2000;41(1):50-4.
12. Katzenstein DA, et al. HIV therapeutics: confronting adherence. J Assoc Nurses AIDS Care 1997;8(Suppl):46-58.
13. Williams AB, et al. Medication adherence in HIV infected women. Presented at the International Conference on AIDS and STDs; 1998; Geneva; 1998.
14. Davis SM, et al. Successful ritonavir induction: intensive patient management. Presented at the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC). Abstract 541; 1997. http://www. retroconference.org/retrovirus97/frameset5.htm.
15. Wenger N, et al. Patient characteristics and attitudes associated with antiretroviral adherence. Presented at the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. Abstract 98; 1999. http://www.retroconference.org/abstracts/abstracts/session92/739.htm.